ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer

European Journal of Cancer

Volumn 49, Issue 1, 2013, Pages 121-131

  Matulonis, Ursula A ^a   Lee, Julie ^a   Lasonde, Brian ^a   Tew, William P ^b   Yehwalashet, Afra ^b   Matei, Daniela ^c   Behbakht, Kian ^d   Grothusen, Jill ^d   Fleming, Gini ^e   Lee, Nita K ^e   Arnott, Jamie ^f,g   Bray, Mark R ^f,g   Fletcher, Graham ⁱ   Brokx, Richard D ⁱ   Castonguay, Vincent ^h   MacKay, Helen ^h   Sidor, Carolyn F ^f,g   Oza, Amit M ^h  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f EntreMed Inc   (United States)

^g ENTREMED INC   (United States)

^h PRINCESS MARGARET HOSPITAL   (Canada)

ⁱ Ampbell Family Institute for Cancer Research   (United States)

Author keywords

ENMD 2076; Phase II; Recurrent ovarian cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRIVANIB; CEDIRANIB; DOXORUBICIN; ENMD 2076; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ADULT; AGED; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GRADING; CANCER GROWTH; CLEAR CELL CARCINOMA; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ENDOMETRIOID CARCINOMA; FATIGUE; FEMALE; HEART LEFT VENTRICLE FAILURE; HISTOLOGY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MITOSIS INDEX; OPEN STUDY; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PHENOTYPE; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; THYROID DISEASE; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PYRAZOLES; PYRIMIDINES; YOUNG ADULT;

EID: 84871416340     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.07.020     Document Type: Article

References (30)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer Statistics 2012 CA Cancer J Clin Jan-Feb 62 1 2012 10 29
2. G.M. Mantia-Smaldone, R.P. Edwards, and A.M. Vlad Targeted treatment of recurrent-platinum resistant ovarian cancer; current and emerging therapies Cancer Manage Res 3 2011 25 38
3. G.C. Fletcher, R.D. Brokx, and T.A. Denny ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action Mol Cancer Ther 10 1 2011 126 137
4. J.R. Diamond, B.R. Bastos, and R.J. Hansen Phase 1 safety, pharmacokinetic and pharmacodynamics study of ENMD-2076, a novel angiogenic and aurora kinase inhibitor in patients with advanced solid tumors Clin Cancer Res 174 2011 849 860
5. A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma; a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322 (Pubitemid 32642183)
6. R.A. Burger, M.W. Sill, B.J. Monk, B.E. Greer, and J.I. Sorosky Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study J Clin Oncol 25 2007 5165 5171 (Pubitemid 350237599)
7. R. Brookmeyer, and J. Crowley A confidence interval for themedian survival time Biometrics 38 1982 29 41
8. K.R. Cho, and L.M. Shih Ovarian cancer Ann Rev Pathol Mech Dis 4 2007 287 313
9. U.A. Matulonis, S. Berlin, and P. Ivy Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer J Clin Oncol 27 2009 5601 5606
10. E.L. Strevel, D.J. Ing, and L.L. Siu Molecularly targeted oncology therapeutics and prolongation of the QT interval J Clin Oncol 25 2007 3362 3371 (Pubitemid 47325624)
11. M. Schmidinger, C.C. Zielinski, and U.M. Vogl Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 32 2008 5204 5212
12. J. Frances, M.S. Ahluwalia, and M. Wetzler Reversible cardiotoxicity with tyrosine kinase inhibitors Clin Adv Hematol Oncol 8 2010 128 135
13. C. Vaklavas, D. Lenihan, R. Kurzrock, and A.M. Tsimberidou Anti-vascular endothelial growth factor therapies and cardiovascular toxicity; what are the important clinical markers to target? Oncologist 15 2010 134 141
14. S.R. Hayman, N. Leung, J.P. Grande, and V.D. Garovic VEGF inhibition, hypertension, and renal toxicity Curr Oncol Rep 14 4 2012 285 294
15. T.K. Choueiri, A.B. Fabio, Y.J. Schutz, Y. Je, J.E. Rosenberg, and J. Bellmunt Risk of arterial thromboembolic events with sunitinib and sorafenib; a systematic review and met-analysis of clinical trials J Clin Oncol 28 2010 2280 2285
16. S.P. Ivy, J.Y. Wick, and B.M. Kaufman An overview of small-molecule inhibitors of VEGFR signaling Nat Rev Clin Oncol 6 2009 569 579
17. M. Grossman, E. Premaratne, J. Desai, and I.D. Davis Thyrotoxicosis during sunitinib treatment for renal cell carcinoma Clin Endocrinol 69 2008 669 672
18. J.M.G. Larkin, L.M. Pyle, and M.E. Gore Fatigue in renal cell carcinoma; the hidden burden of current targeted therapies Oncologist 15 2010 1135 1146
19. M. Scartozzi, E. Galizia, S. Chiorrini, C. Berardi, C. Pierantoni, and S. Cascinu Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab Ann Oncol 20 2009 227 230
20. H.M.E. Verheul, and H.M. Pinedo Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition Nat Rev Cancer 7 2007 475 485 (Pubitemid 46809172)
21. S. Cannistra, U.A. Matulonis, and R.T. Person Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 2007 5180 5186 (Pubitemid 350232248)
22. T.J. Perren, A.M. Swart, and J. Pfisterer A phase 3 trial of bevacizumab in ovarian cancer N Engl J Med 365 2011 2484 2496
23. R.A. Burger, M.F. Brady, and M.A. Bookman Incorporation of bevacizumab in the primary treatment of ovarian cancer N Engl J Med 365 26 2011 2473 2483
24. C. Aghajanian, S.V. Blank, and B.A. Goff OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer J Clin Oncol 30 2012 2039 2045
25. M. Friedlander, K.C. Hancock, and D. Rischin A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer Gynecol Oncol 119 2010 32 37
26. 2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: A Gynecologic Oncology Group study Gynecol Oncol 101 2006 436 440 (Pubitemid 43729968)
27. E.S. Han, R.A. Burger, and K.M. Darcy Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer Gynecol Oncol 114 2010 484
28. S. Mabuchi, C. Kawase, and D.A. Altomare Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary Mol Cancer Ther 9 2010 2411 2422
29. Y.Y. Lee, T.J. Kim, and M.J. Kim Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis Gynecol Oncol 122 2011 541 547
30. M.S. Anglesio, J. George, and H. Kulbe IL6-Stat3-HIF signaling and therapeutic response to the angiogenesis inhibitor, sunitinib, in ovarian clear cell cancer Clin Cancer Res 17 2011 2538 2548